From Financial Modeling Prep: 2024-12-22 16:00:02

Aytu BioPharma, Inc. (NASDAQ:AYTU) and peers like Co-Diagnostics, Inc., AIM ImmunoTech Inc., iBio, Inc., and OpGen, Inc. are facing challenges in capital efficiency. Aytu’s ROIC of -13.90% and WACC of 22.77% indicate inefficiencies in capital utilization. Comparative analysis shows industry-wide struggles in generating returns above the cost of capital.



Read more at Financial Modeling Prep:: Aytu BioPharma, Inc. (NASDAQ:AYTU) Financial Perfo…